Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danil V Makarov

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Urologic Oncology|May 11, 2011
New technology in urology: balancing risk and rewardDanil V Makarov
The Journal of Urology|December 17, 2009
Editorial commentDanil V Makarov
European Urology|April 14, 2009
Editorial comment on: Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in FinlandDanil V Makarov
The Journal of Urology|September 18, 2009
Editorial commentDanil V Makarov
Future Oncology (London, England)|October 6, 2015
Regional variations in US cancer imaging data: a warning for imaging overuseDanil V Makarov, Gemma Westcott
Nature Reviews. Urology|July 14, 2011
Prostate cancer: PSA velocity in prostate cancer screening--the debate continuesMichael S Borofsky, Danil V Makarov
Reviews in Urology|September 21, 2006
The predictive capability of prostate-specific antigen kineticsDanil V Makarov, Alan W Partin
Reviews in Urology|December 29, 2006
Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostateDanil V Makarov, Alan W Partin
Urologic Oncology|December 2, 2006
Nucleic acid-based marker approaches to urologic cancersRobert W Veltri, Danil V Makarov
The Journal of Urology|November 7, 2006
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostateDanil V Makarov, H Ballentine Carter
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Urologic Oncology|May 11, 2011
New technology in urology: balancing risk and rewardDanil V Makarov
The Journal of Urology|December 17, 2009
Editorial commentDanil V Makarov
European Urology|April 14, 2009
Editorial comment on: Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in FinlandDanil V Makarov
The Journal of Urology|September 18, 2009
Editorial commentDanil V Makarov
Future Oncology (London, England)|October 6, 2015
Regional variations in US cancer imaging data: a warning for imaging overuseDanil V Makarov, Gemma Westcott
Nature Reviews. Urology|July 14, 2011
Prostate cancer: PSA velocity in prostate cancer screening--the debate continuesMichael S Borofsky, Danil V Makarov
Reviews in Urology|September 21, 2006
The predictive capability of prostate-specific antigen kineticsDanil V Makarov, Alan W Partin
Reviews in Urology|December 29, 2006
Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostateDanil V Makarov, Alan W Partin
Urologic Oncology|December 2, 2006
Nucleic acid-based marker approaches to urologic cancersRobert W Veltri, Danil V Makarov
The Journal of Urology|November 7, 2006
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostateDanil V Makarov, H Ballentine Carter
Pageof 15